

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **China Regenerative Medicine International Limited**

**中國再生醫學國際有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8158)**

### **LAPSE OF DISCLOSEABLE TRANSACTION RELATING TO CO-OPERATION AGREEMENT IN RELATION TO THE LAB ASSETS OF BIOCELL TECHNOLOGY LIMITED**

Reference is made to the announcement of China Regenerative Medicine International Limited (the “**Company**”) dated 21 August 2019 (the “**Announcement**”) in relation to the co-operation agreement (the “**Agreement**”) entered into between BioCell Technology Limited, a wholly owned subsidiary of the Company and Miskawaan Biotech Limited (“**Miskawaan**”) on 21 August 2019. Unless otherwise defined, capitalized terms used in this announcement have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, completion of the Co-operation is conditional on the fulfillment (or waiver) of the conditions precedent set out in the Agreement. As of 17 December 2019, certain conditions precedent have not been fully fulfilled (or waived if applicable), the Co-operation had lapsed and will not be proceeded. Save for the return of the deposit in the sum of HK\$2,100,000 paid by Miskawaan, the Company does not have any obligation under the Agreement.

The Board considers that the lapse of the Co-operation does not have any material adverse impact on the business operation and financial position of the Group and the interests of its shareholders as a whole.

By Order of the Board  
**China Regenerative Medicine International Limited**  
**Wang Chuang**  
*Chairman*

Hong Kong, 17 December 2019

*As at the date of this announcement, the executive Directors are Mr. Wang Chuang (Chairman) and Mr. Wang Xuejun (Chief Executive Officer); the non-executive Directors are Dr. Ray Yip and Mr. Wu Weiliang; and the independent non-executive Directors are Dr. Fang Jun, Ms. Wang Danjuan and Ms. Yang Ying.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of the publication and will be published on the website of the Company at [www.crimi.hk](http://www.crimi.hk).*